HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways

다국어 초록 (Multilingual Abstract)

The increased expression of receptors for advanced glycation endproduct (RAGE) is known as a key player in the progression of vascular remodeling.
However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)- induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPKRAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.

참고문헌 (Reference)

• 1 Schmidt AM, "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses" 108 : 949-955, 2001
• 2 Hreggvidsdottir HS, "The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation" 86 : 655-662, 2009
• 3 Kang R, "The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics" 33 : 567-577, 2014
• 4 Porto A, "Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein" 20 : 2565-2566, 2006
• 5 Doran AC, "Role of smooth muscle cells in the initiation and early progression of atherosclerosis" 28 : 812-819, 2008
• 6 Simard E, "Receptor for advanced glycation end-products signaling interferes with the vascular smooth muscle cell contractile phenotype and function" 10 : e0128881-, 2015
• 7 Cai Y, "Rap1 induces cytokine production in pro-inflammatory macrophages through NFκB signaling and is highly expressed in human atherosclerotic lesions" 14 : 3580-3592, 2015
• 8 Yan SD, "RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease" 382 : 685-691, 1996
• 9 Schmidt AM, "RAGE : a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes" 11 : 368-375, 2000
• 10 Bierhaus A, "Multiple levels of regulation determine the role of the receptor for AGE(RAGE)as common soil in inflammation, immune responses and diabetes mellitus and its complications" 52 : 2251-2263, 2009
• 11 Burke AP, "Morphologic findings of coronary atherosclerotic plaques in diabetics : a postmortem study" 24 : 1266-1271, 2004
• 12 Newby AC, "Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates" 69 : 614-624, 2006
• 13 Umahara T, "Local extension of HMGB1 in atherosclerotic lesions of human main cerebral and carotid arteries" 29 : 235-242, 2014
• 14 Kalinina N, "Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions : role of activated macrophages and cytokines" 24 : 2320-2325, 2004
• 15 Chistiakov DA, "Human miR-221/222 in physiological and atherosclerotic vascular remodeling" 2015 : 354517-, 2015
• 16 Wang K, "High mobility group box 1 mediates interferon-γ-induced phenotypic modulation of vascular smooth muscle cells" 118 : 518-529, 2017
• 17 Zou H, "HMGB1is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs" 14 : 1765-1777, 2014
• 18 Andersson U, "HMGB1 is a therapeutic target for sterile inflammation and infection" 29 : 139-162, 2011
• 19 Jang EJ, "HMGB1 enhances AGE-mediated VSMC proliferation via an increase in 5-LO-linked RAGE expression" 118-119 : 106559-, 2019
• 20 Liang Y, "HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2" 405 : 63-71, 2015
• 21 IndolfiC, "Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats" 103 : 2980-2986, 2001
• 22 Schwencke C, "Decreased caveolin-1 in atheroma : loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis" 68 : 128-135, 2005
• 23 Rakesh K, "Cytokines and growth factors involved in apoptosis and proliferation of vascular smooth muscle cells" 5 : 1487-1506, 2005
• 24 Land WG, "Chronic allograft dysfunction : a model disorder of innate immunity" 36 : 209-228, 2013
• 25 원선미 ; 박연희 ; 김희정 ; 박권무 ; 이원정, "Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway" 생화학분자생물학회 38 (38): 525-534, 2006
• 26 Dinarello CA, "Biologic basis for interleukin-1 in disease" 87 : 2095-2147, 1996
• 27 Leclerc E, "Binding of S100 proteins to RAGE : an update" 1793 : 993-1007, 2009